Cardiovascular Adverse Events Reported from COVID-19 Vaccines: A Study Based on WHO Database

References

• World Health Organisation. WHO coronavirus disease (COVID-19) dashboard; 2021 [ cited March 24, 2021]. Available from: https://covid19.who.int/. Accessed July 16, 2021.
   Google Scholar
• Craven J. Regulatory Focus: COVID-19 vaccine tracker: Regulatory Affairs Professionals Society (RAPS); 2021 [ updated March 25, 2021; cited March 31, 2021]. Available from: https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker. Accessed July 16, 2021.
   Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al.; C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603–2615. doi:10.1056/NEJMoa2034577.
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, et al.; COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403–416. doi:10.1056/NEJMoa2035389
   PubMed Web of Science ®Google Scholar
• Voysey M, Clemens SAC, Madhi SA, et al.; Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. COVID-19 Vaccine AstraZeneca: PRAC investigating cases of thromboembolic events - vaccine’s benefits currently still outweigh risks – Update; 2021 [ updated March 11, 2021; cited March 31, 2021]. Available from: https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-prac-investigating-cases-thromboembolic-events-vaccines-benefits. Accessed July 16, 2021.
   Google Scholar
• Medical News Today. New SARS-CoV-2 variants: how can vaccines be adapted?; 2021 [ cited March 31, 2021]. Available from: https://www.medicalnewstoday.com/articles/new-sars-cov-2-variants-how-can-vaccines-be-adapted. Accessed July 16, 2021.
   Google Scholar
• World Health Organisation. The Moderna COVID-19 (mRNA-1273) vaccine: what you need to know; 2021 [ updated January 26, 2021; cited March 20, 2021]. Available from: https://www.who.int/news-room/feature-stories/detail/the-moderna-covid-19-mrna-1273-vaccine-what-you-need-to-know?gclid=CjwKCAjwxuuCBhATEiwAIIIz0Q-MTsc3acAzhBS0gcljbpVRGF5zH7tZaPHRg0SXlsj8ZZPWQRODtBoCuogQAvD_BwE. Accessed July 16, 2021.
   Google Scholar
• Lee EJ, Cines DB, Gernsheimer T, et al. Thrombocytopenia following pfizer and moderna SARS-CoV-2 vaccination. Am J Hematol. 2021;96(5):534–537. doi:10.1002/ajh.26132
   PubMed Web of Science ®Google Scholar
• Torjesen I. Covid-19: Norway investigates 23 deaths in frail elderly patients after vaccination. BMJ. 2021;372:n149.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. COVID-19 ACIP vaccine recommendations; 2021 [ updated March 2, 2021; cited March 22, 2021]. Available from: https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/covid-19.html. Accessed July 16, 2021.
   Google Scholar
• Uppsala Monitoring Centre: WHO Programme for International Drug Monitoring. VigiBase; 2020 [ cited October 10 2020]. Available from: https://www.who-umc.org/vigibase/vigibase/. Accessed July 16, 2021.
   Google Scholar
• Charan J, Kaur RJ, Bhardwaj P, et al. Rapid review of suspected adverse drug events due to remdesivir in the WHO database; findings and implications. Expert Rev Clin Pharmacol. 2021;14(1):95–103. doi:10.1080/17512433.2021.1856655
   PubMed Web of Science ®Google Scholar
• Kaur RJ, Charan J, Dutta S, et al. Favipiravir Use in COVID-19: analysis of suspected adverse drug events reported in the WHO database. Infect Drug Resist. 2020;13:4427–4438. doi:10.2147/IDR.S287934
   PubMed Web of Science ®Google Scholar
• Charan J, Dutta S, Kaur R. et al. Tocilizumab in COVID-19: a study of adverse drug events reported in the WHO database. Expert Opin Drug Saf. 2021;1–12. doi:10.1080/14740338.2021.1946513
   Web of Science ®Google Scholar
• Dutta S, Kaur RJ, Bhardwaj P, et al. Hydroxychloroquine as therapeutic option in COVID-19: analysis of suspected cardiovascular adverse drug events reported in the vigibase. Bangladesh j Med Sci. 2021;20(4):897–910. doi:10.3329/bjms.v20i4.54150
   Web of Science ®Google Scholar
• Kaur RJ, Dutta S, Bhardwaj P, et al. Adverse events reported from COVID-19 vaccine trials: a systematic review. Indian J Clin Biochem. 2021;21–23 doi:10.1007/s12291-021-00968-z
   Web of Science ®Google Scholar
• Glenn DA, Hegde A, Kotzen E, et al. Systematic review of safety and efficacy of COVID-19 vaccines in patients with kidney disease. Kidney Int Rep. 2021;6(5):1407–1410. doi:10.1016/j.ekir.2021.02.011
   PubMed Web of Science ®Google Scholar
• Dutta S, Kaur RJ, Charan J, et al. Serious adverse events reported from the COVID-19 vaccines: a descriptive study based on WHO database. medRxiv. 2021. doi:10.1101/2021.03.23.21253433
   Google Scholar
• Uppsala Monitoring Centre: WHO Programme for International Drug Monitoring. VigiBase FAQs; [ updated September 16, 2020]. Available from: https://www.who-umc.org/vigibase/vigibase/know-more-about-vigibase/. Accessed March 7, 2021.
   Google Scholar
• Uppsala Monitoring Centre. VigiBase: signaling harm and pointing to safer use. Available from: https://www.who-umc.org/vigibase/vigibase/vigibase-signalling-harm-and-pointing-to-safer-use/. Accessed October 10, 2020.
   Google Scholar
• World Health Organization. WHO Collaborating Centre for Drug Statistics Methodology; [ updated August 17, 2020]. Available from: https://www.whocc.no/. Accessed April 12, 2021.
   Google Scholar
• Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20(2):109–117. doi:10.2165/00002018-199920020-00002
   PubMed Web of Science ®Google Scholar
• International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Medical Dictionary for Regulatory Activities (MedDRA). Available from: https://www.meddra.org/how-to-use/support-documentation/english/welcome. Accessed April 12, 2021.
   Google Scholar
• Medical Dictionary for Regulatory Activities (MedDRA). MedDRA Hierarchy. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Available from: https://www.meddra.org/how-to-use/basics/hierarchy. Accessed April 12, 2021.
   Google Scholar
• Uppsala Monitoring Centre. Glossary of pharmacovigilance terms; [ updated September 12, 2020]. Available from: https://www.who-umc.org/global-pharmacovigilance/publications/glossary/. Accessed April 12, 2021.
   Google Scholar
• International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Maintenance of the ich guideline on clinical safety data management: data elements for transmission of individual case safety report E2B(R2); March 9, 2021. Available from: https://admin.ich.org/sites/default/files/inline-files/E2B_R2_Guideline.pdf. Accessed March 9, 2021.
   Google Scholar
• Bate A, Lindquist M, Edwards IR, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54(4):315–321. doi:10.1007/s002280050466
   PubMed Web of Science ®Google Scholar
• Montastruc JL, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol. 2011;72(6):905–908. doi:10.1111/j.1365-2125.2011.04037.x
   PubMed Web of Science ®Google Scholar
• Li C, Xia J, Deng J, et al. A comparison of measures of disproportionality for signal detection on adverse drug reaction spontaneous reporting database of Guangdong province in China. Pharmacoepidemiol Drug Saf. 2008;17(6):593–600. doi:10.1002/pds.1601
   PubMed Web of Science ®Google Scholar
• Harpaz R, DuMouchel W, Shah NH, et al. Novel data-mining methodologies for adverse drug event discovery and analysis. Clin Pharmacol Ther. 2012;91(6):1010–1021. doi:10.1038/clpt.2012.50
   PubMed Web of Science ®Google Scholar
• Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18(6):427–436. doi:10.1002/pds.1742
   PubMed Web of Science ®Google Scholar
• Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and moderna vaccines. Eur Rev Med Pharmacol Sci. 2021;25(3):1663–1669.
   PubMed Web of Science ®Google Scholar
• AstraZeneca. COVID-19 vaccine AstraZeneca analysis print; May 30, 2021 [ updated May 20, 2021]. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/972833/COVID-19_AstraZeneca_Vaccine_Analysis_Print.pdf. Accessed May 30, 2021.
   Google Scholar
• FDA Briefing Document: Moderna COVID-19 Vaccine. Vaccines and related biological products advisory committee meeting; [ updated December 17, 2020]. https://www.fda.gov/media/144434/download. Accessed March 9, 2021.
   Google Scholar
• FDA Briefing Document: Pfizer-BioNTech COVID-19 Vaccine. Vaccines and related biological products advisory committee meeting; [ updated March 8, 2021]. Available from: https://www.fda.gov/media/144245/download. Accessed July 16, 2021. Accessed March 18, 2021.
   Google Scholar
• Publishing Service. Government of UK. COVID-19 mRNA Pfizer- BioNTech Vaccine Analysis Print. Updated May 28, 2021. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/989996/COVID-19_mRNA_Pfizer-_BioNTech_Vaccine_Analysis_Print.pdf. Accessed June 4, 2021.
   Google Scholar
• Shimabukuro T Centers for Disease Control and Prevention. COVID-19 vaccine safety update: Advisory Committee On Immunization Practices (ACIP) January 27, 2021. CDC COVID-19 Vaccine Task Force; March 30, 2021. [ updated January 27, 2021]. Available from: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-01/06-COVID-Shimabukuro.pdf. Accessed March 30, 2021.
   Google Scholar
• Boivin Z. Untimely myocardial infarction or COVID-19 vaccine side effect. Cureus. 2021;13(3):e13651. doi:10.7759/cureus.13651
   PubMed Web of Science ®Google Scholar
• Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e139–e596. doi:10.1161/cir.0000000000000757
   PubMed Web of Science ®Google Scholar
• Villarroel MA, Blackwell DL, Jen A. Tables of Summary Health Statistics for U.S. Adults: 2018 National Health Interview Survey. NCHS, National Center for Health Statistics. 2019. Available from: http://www.cdc.gov/nchs/nhis/SHS/tables.htm. Accessed May 29, 2021.
   Google Scholar
• Virani SS, Alonso A, Aparicio HJ, et al. Heart disease, and stroke statistics-2021 update: a report from the American Heart Association. Circulation. 2021;143(8):e254–e743. doi:10.1161/cir.0000000000000950
   PubMed Web of Science ®Google Scholar
• Zeng Z, Chen J, Xiao C, Chen W. A global view on prevalence of hypertension and human develop index. Ann Glob Health. 2020;86(1):67. doi:10.5334/aogh.2591
   PubMed Web of Science ®Google Scholar
• Huxley RR, Lopez FL, Folsom AR, et al. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2011;123(14):1501–1508. doi:10.1161/circulationaha.110.009035
   PubMed Web of Science ®Google Scholar
• Khurshid S, Choi SH, Weng LC, et al. Frequency of cardiac rhythm abnormalities in a half million adults. Circ Arrhythm Electrophysiol. 2018;11(7);e006273. doi:10.1161/circep.118.006273
   PubMed Web of Science ®Google Scholar
• Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications. Arch Intern Med. 1995;155(5):469–473. doi:10.1001/archinte.1995.00430050045005
   PubMedGoogle Scholar
• Lindberg T, Wimo A, Elmståhl S, Qiu C, Bohman DM, Sanmartin Berglund J. Prevalence and incidence of atrial fibrillation and other arrhythmias in the general older population: findings from the Swedish National Study on aging and care. Gerontol Geriatr Med. 2019;5:2333721419859687. doi:10.1177/2333721419859687
   Web of Science ®Google Scholar
• Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge. Int J Stroke. 2021;16(2):217–221. doi:10.1177/1747493019897870
   PubMed Web of Science ®Google Scholar
• Khan MA, Hashim MJ, Mustafa H, et al. Global epidemiology of Ischemic heart disease: results from the Global Burden of Disease Study. Cureus. 2020;12(7):e9349. doi:10.7759/cureus.9349
   PubMed Web of Science ®Google Scholar
• Quer G, Gadaleta M, Radin JM, et al. The physiologic response to COVID-19 vaccination. he physiologic response to COVID-19 vaccination. medRxiv [Preprint]. 2021. doi:10.1101/2021.05.03.21256482
   Google Scholar
• World Health Organization. Immunization stress-related responses. A Manual. Available from: https://www.who.int/publications/i/item/978-92-4-151594-8. Accessed June 4, 2021.
   Google Scholar
• Medicines and Healthcare products Regulatory Agency. Coronavirus vaccine - weekly summary of Yellow Card reporting; [ updated Jun 3, 2021]. Available from: https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting. Accessed June 4, 2021.
   Google Scholar
• Meylan S, Livio F, Foerster M, Genoud PJ, Marguet F, Wuerzner G. Stage III hypertension in patients after mRNA-based SARS-CoV-2 Vaccination. Hypertension. 2021;77(6):e56–e57. doi:10.1161/HYPERTENSIONAHA.121.17316
   PubMed Web of Science ®Google Scholar